No but it is close. I was not all that clear in what I was trying to say. It was at last years cap raising round of meetings they had in Brisbane Sydney and Melbourne, where here in Melb the question was asked re the licensing deal ie would the one license cover all types of cancers and so block out all other contenders. This was not to be the case. The intention was to license one company for one cancer specific treatment, so they could in fact be dealing with multiple partners. But this also did not preclude if I recall correctly still the one company picking up all the potential licenses.
PGL Price at posting:
0.0¢ Sentiment: LT Buy Disclosure: Held